NVCT (Nuvectis Pharma) OCF Margin %: 0.00% (As of Mar. 2026)


NVCT Nuvectis Pharma Inc NVCT
22 GF Score
Price $27.19
! 2 Warning Signs
View Full Analysis

What is Nuvectis Pharma OCF Margin %?

Nuvectis Pharma NVCT -2.44% 22 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates NVCT with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Nuvectis Pharma ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Nuvectis Pharma's Cash Flow from Operations for the three months ended in Mar. 2026 was $-6.51 Mil. Nuvectis Pharma's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Nuvectis Pharma's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Nuvectis Pharma's current OCF Yield % is -2.54%.

The historical rank and industry rank for Nuvectis Pharma's OCF Margin % or its related term are showing as below:


NVCT's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Nuvectis Pharma OCF Margin % Related Terms

Nuvectis Pharma OCF Margin % Historical Data

* Premium members only.

The historical data trend for Nuvectis Pharma's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuvectis Pharma OCF Margin % Chart

Nuvectis Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Nuvectis Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NVCT
22GF Score
Nuvectis Pharma Inc NVCT
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nuvectis Pharma OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Nuvectis Pharma's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-16.009/0
= %

Nuvectis Pharma's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-6.511/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Nuvectis Pharma (NVCT) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Nuvectis Pharma and its competitors. According to the industry distribution chart, Nuvectis Pharma ranks #999999 out of 959 companies in the Biotechnology industry.
Is Nuvectis Pharma's OCF Margin % too high?
Nuvectis Pharma's current OCF Margin % is 0.00%. Based on the distribution chart, Nuvectis Pharma ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nuvectis Pharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Nuvectis Pharma's OCF Margin % compare to ALXO and TARA?
According to the Biotechnology industry distribution chart, Nuvectis Pharma ranks #999999 out of 959 companies for OCF Margin %. This places Nuvectis Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Nuvectis Pharma and its competitors. Nuvectis Pharma's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvectis Pharma stock overvalued right now?
Nuvectis Pharma (NVCT) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Nuvectis Pharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Nuvectis Pharma (NVCT), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuvectis Pharma Business Description

Address 1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
22GF Score

Get the complete analysis for NVCT

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.19
Price